NUS researchers develop revolutionary technology to unravel complex protein interactions that could transform cancer diagnostics
Scalable and adaptable, TETRIS captures the diversity of protein interactions on site to inform accurate cancer diagnoses, enabling the personalisation of ensuing treatments. SINGAPORE, Sept. 30, 2024 /PRNewswire/ -- A team of researchers from the National University of Singapore's (NUS) Institute for Health Innovation & Technology (iHealthtech), led by Associate Professor Shao Huilin and Associate Professor...
Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Severe Hypertriglyceridemia
HANGZHOU, China, Sept. 30, 2024 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting Fibroblast growth factor 21 receptor (FGF21R), Glucagon-like peptide-1 receptor (GLP-1R), and Glucagon receptor (GCGR)...
IASO Bio Scientist and Leading Chinese Physicians in Onco-Hematology Visit Hematology Center at the State University of Campinas, Brazil, to Explore Cooperation in Cancer Treatment
SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 30, 2024 /PRNewswire/ -- On September 23, in Rio de Janeiro, on the eve of the International Myeloma Society (IMS) Annual Meeting, Dr. Yongke Zhang, Chief Scientific Officer of IASO Biotherapeutics (IASO Bio), along with leading Chinese onco-hematology physicians, including Professor Lugui Qiu from the Chinese Academy of Medical Sciences Hematology...
Akeso’s Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population
HONG KONG, Sept. 30, 2024 /PRNewswire/ -- September 30, 2024, Akeso (9926. HK) announced that its internally developed PD-1/CTLA-4 bispecific antibody, cadonilimab, has received approval from the National Medical Products Administration (NMPA) for a new indication: cadonilimab in combination with fluoropyrimidine and platinum-based chemotherapy for first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal...
World’s First Carbon Neutral Salad: The Revolutionary Drinkable Salad that’s Good for You and the Planet
HONG KONG, Sept. 29, 2024 /PRNewswire/ -- Tired of sacrificing taste for nutrition? Try Future Salad, the world's first carbon-neutral drinkable salad. It supports a healthy lifestyle and combats climate change. In September 2024, on its 4th anniversary, Future Salad completed a Series A funding round to expand into new markets and develop products. ...
World’s First Carbon Neutral Salad: The Revolutionary Drinkable Salad that’s Good for You and the Planet
HONG KONG, Sept. 29, 2024 /PRNewswire/ -- Tired of sacrificing taste for nutrition? Try Future Salad, the world's first carbon-neutral drinkable salad. It supports a healthy lifestyle and combats climate change. In September 2024, on its 4th anniversary, Future Salad completed a Series A funding round to expand into new markets and develop products. ...
Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor’s Portfolio of next-generation CDK inhibitors for the Treatment of Breast Cancer
Genentech will acquire Regor's next-generation CDK inhibitors for an upfront payment of $850 million in cash. Regor is also eligible to receive additional cash payments contingent on achieving future development, regulatory and commercial milestones CAMBRIDGE, Mass., Sept. 30, 2024 /PRNewswire/ -- Regor Pharmaceuticals (USA) ("Regor") has entered into a definitive purchase agreement whereby Genentech, a member of the...
Alphamab Oncology and CSPC Achieved a Licensing Agreement on Anti-HER2 Bispecific ADC JSKN003 in Mainland China
SUZHOU, China, Sept. 30, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Alphamab"), a wholly-owned subsidiary of Alphamab Oncology ("the Company"), entered into a licensing agreement (the "Licensing Agreement") on anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 with JMT-Bio Technology Co., Ltd. ("JMT-Bio"), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd....
Herbalgy 25th Anniversary – Touch Cool- Peppermint Cooling to Soothe Various Pains Anytime, Anywhere
HONG KONG, Sept. 30, 2024 /PRNewswire/ -- Since its establishment in 1999, Herbalgy Pharmaceutical Ltd. has been dedicated to developing products that meet the diverse needs of Hong Kong people. In addition to the "Herbalgy" brand, they have launched two other brands, "Touch Cool" and "Tibet Red," over the past 25 years. The...
Mun Australia Introduces GloveOn COATS® Biodegradable Nitrile Gloves for Enhanced Skin Health and Sustainability
SYDNEY, Sept. 30, 2024 /PRNewswire/ -- Skin irritation is a common concern for workers who frequently wear gloves, and there's an increasing awareness of the need for sustainable product choices. This has led to a growing demand for gloves that not only protect the skin but also minimize environmental impact. In response, Mun Australia has launched its new GloveOn...
